Bright Minds Biosciences' CEO, Ian McDonald, shares update on the company's multiple clinical trials.
Similar Posts
Psychedelic Spotlight Interview with Daniel Carcillo
In this episode of the Psychedelic Spotlight podcast, we catch…
The Mainstream Media GETS Psychedelic Stocks [Like MMEDF, CMPS, EHVVF & FTRPF]
Hello psychedelic investors! Today’s episode will be a little different. We will discuss the recent media coverage of psychedelic stocks and its role in psychedelic inspired companies’ future.
It appears that the mainstream media understands the potential for psychedelic stocks to disrupt the pharmaceutical Industry. Now understanding what this means, and its implications is extremely important for retail investors like you and me.
We’ll also zoom into one piece of media about MindMed (MMED/MMEDF) and Compass Pathways (CMPS), and explore how it hits the nail on the head.
We are going to do this because one, it’s a good article that I wanted to share with you
And two, it exemplifies my point that the mainstream understands the potential here, and might actually be on the right side of history.
P.S. I mention in the video that the article I’m discussing is by Yahoo Finance. It turns out the article is from OTC stock review.
For those interested in reading the entire article: https://ca.movies.yahoo.com/264-million-reasons-psychedelic-stocks-133000885.html
Time Stamps
0:00 – Intro
3:10 – Media Coverage on Tesla & Psychedelic Stocks
6:36 – Benefits of the media covering Psychedelic Companies like (MMEDF & CMPS)
8:05 – Influence on stock valuations and stealth investors
10:57 – 264 Million Reasons Why Psychedelic Stocks Have More Room To Grow
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
My 5-MeO-DMT Psychedelic Experience in Tepotzlan Mexico | Tandava Retreats
In this short vlog, Swati Sharma, Media Director of PsychedelicSpotlight.com…
Top 5 Catalysts for Psychedelic Stocks In The Second Half of 2021 (MNMD,CMPS,ATAI,TRYP, CYBN & MORE)
What are top 5 catalysts for psychedelic stocks in the second half of 2021? Stay tuned to hear how stocks like MindMed (NASDAQ: MNMD),
(NEO:MMED), Compass Pathways (NASDAQ: CMPS), atai Life Sciences ( NASDAQ: ATAI), Tryp Therapeutics, Cybin and more will affect the psychedelic industry in 2021.
Timestamps:
0:00 – Intro
1:38 – #5: A New Psychedelics ETF (PSIL)
4:57 – #4:California Decriminalizing possession of psychedelics, and Legalising the personal production of Psilocybin
7:30 – #3:The commencement of MANY phase 2a trials
10:16 – #2: MindMed’s Project Lucy phase 2b trial begins
11:47 – #1: Compass Pathways phase 2b trial results released
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Check out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
#MindMed #MNMD #PsychedelicStocks
Interview with James Lanthier, CEO of Mindset Pharma
CEO of Mindset Pharma, James Lanthier, gives us an overview of his company and the 4 new psychedelics they are creating. He also discusses some big breaking news!
CYBIN CEO Doug Drysdale On How CYB-003 Is Better Than Psilocybin | Next Gen Psychedelics
In this episode of the Spotlight On, James Hallifax from…